The concept stocks of weight loss drugs rose before the US stock market closed
海角七号
发表于 2024-12-7 20:26:16
188
0
0
According to AI News, on November 26th, the concept stocks of weight loss drugs rose in the US stock market, with Novo Nordisk rising more than 2% and Eli Lilly rising nearly 2%. The report states that Biden proposed to cover weight loss drugs with medical insurance and medical subsidies.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Overview | The 'Trump Deal' Explosion! What are the concept stocks?
- Lai Lai scares, Novo Nordisk saves the scene! The market prospects of weight loss drugs still make many players salivate
- Most of the anti epidemic concept stocks in the US stock market fell, while Moderna fell more than 7%
- AI application explosion giant has risen more than 7 times! High frequency institutional research+exposure of AI application concept stocks with high research and development capabilities
- The US stock market closed higher, with all three major indices hitting historic highs. Cryptocurrency concept stocks surged sharply
- Global markets: Nasdaq, S&P 500 index set new historical highs, cryptocurrency concept stocks rise
- Soaring 138%! The rise of new trends? Quantum concept stocks in the US stock market collectively soar
- Weekly Outlook | US CPI may shake expectations of Fed interest rate cuts! Oracle and Broadcom announce their performance, will it affect the subsequent trend of AI concept stocks?
- Quantum technology concept stocks in the US stock market continue to rise, with Quantum Computing rising by over 36%
- Clinical data falls short of expectations, weight loss drug giant's market value evaporates $62.5 billion
